Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 1.00 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 1.00 |
| ▸ | F2 | P00734 | 3/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 2/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.97 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.97 |
| ▸ | F7 | P08709 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361696 | 1.00 | F10 (1.00) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL29354281 | 0.93 | F10 (1.00) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL29503461 | 0.90 | F10 (0.82) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL30697529 | 0.89 | F10 (0.80) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL27659973 | 0.88 | F10 (0.78) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL65730 | 0.87 | F10 (0.77) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL28757174 | 0.86 | F10 (0.76) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL29625940 | 0.86 | F10 (0.76) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL4322200 | 0.86 | TPSAB1 (0.78) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL27639306 | 0.85 | F10 (0.74) | F10TPSAB1F2PRSS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | claimed |
| CN-113679931-A | Drug coated balloon | 因特尔赛克特耳鼻喉公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113423454-A | Expandable member systems and methods for drug delivery | 因特尔赛克特耳鼻喉公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-107427668-B | Drug coated balloon | 因特尔赛克特耳鼻喉公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-212140660-U | Degradable lacrimal duct tube | 上海视鉴医疗器械有限公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7947741-B2 | Use and administration of bacterial efflux pump inhibitors | MPEX PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | ABCB11, SLC47A2, SLC47A1 | F10 3948/4885TPSAB1 2872/4885F2 4843/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | F10 4311/4885TPSAB1 3148/4885F2 4320/4885 |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | F10 1069/4885TPSAB1 202/4885F2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.